mCRPC VL

The Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade - Wassim Abida

Details
Wassim Abida joins Charles Ryan in a discussion on a JAMA Oncology published paper on the Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. Wassim details the prevalence of MSI-H/dMMR prostate cancer and the clinical benefit of anti–PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy in this molecularly defined population. The...

Introducing TIN 117m for Convention Electron Therapy of mCRPC - Suresh Srivastava

Details
Suresh C. Srivastava presents the unique opportunities and future for nuclear medicine, including theragnostic radiopharmaceuticals for molecular imaging plus therapy and getting closer to personalized medicine, selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and eval...

Combination Therapies and Quality of Life Data in Prostate Cancer - Fred Saad

Details
(Length of Conversation: 13 min) Charles Ryan and Fred Saad discuss the data results in patients with mCRPC from a combined therapeutic approach with abiraterone and apalutamide. They discuss the rationale and theory behind these results. Later they move to discuss the quality of life analysis for patients with CRPC. A review of the SPARTAN trial and the optimistic results from his work. Biographi...

Prospective Study of Low-Dose Abiraterone with Food Versus Standard Dose Abiraterone in mCRPC - Russell Szmulewitz

Details
(Length of Discussion: 21 min) Russell Szmulewitz talks with Alicia Morgans about a trial that evaluated abiraterone with food and how that might affect relative patient outcomes, such as PSA. This study sought to test the hypothesis that low-dose Abiraterone acetate (AA) (LOW; 250 mg with a low-fat meal) would have comparable activity to standard dosed AA (STD; 1,000 mg fasting) in patients with...

Exercise in Men with Metastatic Castrate-Resistant Prostate Cancer, the INTERVAL Study - Interview with Fred Saad

Details
(Length of Conversation: 9 min) Fred Saad and Charles Ryan discuss the Movember Foundation sponsored, INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer Study (INTERVAL). This is a randomized phase 3 study of exercise in men with metastatic castrate-resistant prostate cancer (mCRPC). The objective of the study is to determine if high intensity aerobic and re...

UPWARD Study - Seizure Rates in Enzalutamide-Treated Men with mCRPC - Susan Slovin

Details
(Length of presentation: 17 min) Alicia Morgans, MD discusses the UPWARD Study with Susan Slovin, MD, PhD. A study Dr. Slovin was a part of conducting to answer the question “Are seizure rates affected by treatment with enzalutamide in patients with metastatic castration-resistant prostate cancer who have seizure risk factors?” Dr. Slovin discusses with Dr. Morgans the reasons for conducting the U...

Sequencing and Combining CRPC Therapies: What Does the Future Hold? - Charles Ryan

Details
Sequencing and Combining CRPC Therapies: What Does the Future Hold? Presentation from the 2017 Annual LUGPA meeting in Chicago, IL (Length of Presentation: 21 min) Dr. Charles Ryan provides a comprehensive overview of CRPC including the natural history of prostate cancer and the many sequences that exist in the treatment of the disease. Dr. Ryan states that CRPC is a broad-spectrum condition so it...

Impacts of Latitude and Stampede: Urologist and Urologic Oncologist's Perspective

Details
(Length of lecture ~ 36 minutes) Alicia Morgans hosts a discussion with David Penson, Charles Ryan and Neal Shore regarding impacts of LATITUDE and STAMPEDE data from a urologist and urologic oncologists perspective, taking in to account the recently updated data from the CHAARTED trial. Specifically, discussed was treating patients that have high-volume, aggressive metastatic prostate cancer that...

Clinical Conversation: CHAARTED, LATITUDE and STAMPEDE

Details
(Length of discussion ~ 27 minutes) Charles Ryan hosts a discussion with Alicia Morgans and Christopher Sweeney regarding data from the LATITUDE, STAMPEDE and CHAARTED trials, and the survivor endpoints for patients receiving initial androgen deprivation therapy (ADT) for metastatic prostate cancer. Specifically, discussed is the interface of these three very important studies and the many treatme...

STAMPEDE and LATITUDE Trials: Issues to Consider - Thomas Keane

Details
Biograhy: Thomas E. Keane Related Content: LATITUDE abstract from ASCO 2017 STAMPEDE abstract from ASCO 2017 STAMPEDE - Clinical Trial Information A Clinical Conversation with Alicia Morgans and Charles Ryan: Considerations of ASCO 2017 LATITUDE and STAMPEDE Crashing into progress: New findings meet old habits
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe